18.10.2020 • News

Dow and JM Win China IP Case

Dow and Johnson Matthey (JM) have won a second court case in China over infringement of their jointly owned LP Oxo technology for producing oxo-alcohols.

The Jiangsu High People’s Court ruled in July that Shanjun Clean Energy Technology had “illicitly obtained and infringed trade secrets” owned by Dow Global Technologies and JM and ordered the Chinese group to pay “significant” compensation.

“The ruling demonstrates fair enforcement of trade secret rights and commitments of the US and China’s Phase One Agreement and China’s commitment to improve intellectual property rights,” said Yoke Loon Lim, president of Dow Greater China. “This enforcement is critical to protect the legitimate operations and economic resiliency of domestic manufacturers in China, the US and around the globe.”

JM’s managing director of efficient natural resources, John Gordon, added that there are 20 plants in China operating licensed LP Oxo technology that will benefit from the ruling.

The case marks the second in China in which Dow and JM have successfully defended their intellectual property for LP Oxo technology. In 2017, an arbitration panel of the Stockholm Chamber of Commerce held that Shandong-based Luxi Chemical Group had violated its secrecy and non-use undertaking by using Dow’s and JM’s protected information in the design, construction and operation of its butanol and 2-ethylhexanol plants.

The court awarded Dow and JM approximately $100 million. The companies said they were pursuing appropriate actions to enforce the award.

Dow and Johnson Matthey have won a court case in China over infringement of...
Dow and Johnson Matthey have won a court case in China over infringement of their jointly owned LP Oxo technology for producing oxo-alcohols. The Jiangsu High People’s Court has awarded “significant” compensation from Shanjun Clean Energy Technology for stealing trade secrets. (c) Arek Socha

Company

Logo:

Dow Chemical Company

2211 HH Dow Way
48674 Midland, MI
US

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read